Compare Citius Pharmaceuticals Inc (CTXR) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Direxion Daily Semiconductor Bear 3X Shares trades at $34.38 (market cap $1.96B). The key difference: Direxion Daily Semiconductor Bear 3X Shares is far larger — about 143.9× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 113,512,541). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.
| CTXR | SOXS | |
|---|---|---|
Market Cap | $13.62M | $1.96B |
Volume | 132,438 | 113,512,541 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $988.00 |
52-Week Low | $0.48 | $29.62 |
Typical Hold Time | 16 Days | 11 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
SOXS, a leveraged inverse ETF tracking the semiconductor sector, trades at $34.12, up 11.34% over 24 hours amid recent semiconductor stock weakness. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. The fund executed a 1:10 stock split in July 2026 and has a dividend scheduled for September 2026. News highlights focus on volatility and tactical use, with articles noting surges during chip sell-offs.
The outlook for SOXS remains highly speculative, suitable only for short-term tactical trades due to its leveraged inverse structure and extreme volatility. Key risks include rapid erosion from semiconductor sector rebounds and structural decay. Investors should avoid long-term holdings, as persistent AI demand could trigger sharp losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
